Cargando…

Impact of minocycline on outcomes of EGFR-mutant non-small cell lung cancer patients treated with EGFR-TKIs

Minocycline is often administered prophylactically or therapeutically to non-small cell lung cancer (NSCLC) patients receiving epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs) for skin rash as an adverse event. We examined the effects of minocycline on the outcomes of EGFR-mut...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tone, Mari, Iwahori, Kota, Shiroyama, Takayuki, Futami, Shinji, Naito, Yujiro, Fukushima, Kiyoharu, Miyake, Kotaro, Koyama, Shohei, Hirata, Haruhiko, Nagatomo, Izumi, Wada, Hisashi, Takeda, Yoshito, Kumanogoh, Atsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10204024/ https://www.ncbi.nlm.nih.gov/pubmed/37221285 http://dx.doi.org/10.1038/s41598-023-35519-4

Ejemplares similares

Management of severe hypertension due to lenvatinib in patients with advanced thymic carcinoma: A case report
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies
por: Matsumoto, Kinnosuke, et al.
Publicado: (2022)

Respiratory Impedance is Associated with Ventilation and Diffusing Capacity in Patients with Idiopathic Pulmonary Fibrosis Combined with Emphysema
por: Yamamoto, Yuji, et al.
Publicado: (2022)

Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients
por: Iwahori, Kota, et al.
Publicado: (2022)

A case of synchronous triple autoimmune disorders secondary to thymoma: Pure red cell aplasia, Good's syndrome, and thymoma-associated multi-organ autoimmunity
por: Nakagawa, Yuta, et al.
Publicado: (2022)

Impact of sarcopenia in patients with advanced non–small cell lung cancer treated with PD-1 inhibitors: A preliminary retrospective study
por: Shiroyama, Takayuki, et al.
Publicado: (2019)

Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review
por: Niitsu, Takayuki, et al.
Publicado: (2020)

COVID‐19 in a human T‐cell lymphotropic virus type‐1 carrier
por: Enomoto, Takatoshi, et al.
Publicado: (2022)

Lateral Decubitus Position Enables Further Advancement of the Bronchoscope into the Lung Periphery
por: Miyake, Kotaro, et al.
Publicado: (2022)

A lung abscess caused by secondary syphilis – the utility of polymerase chain reaction techniques in transbronchial biopsy: a case report
por: Futami, Shinji, et al.
Publicado: (2019)

Identification of CD14 and lipopolysaccharide-binding protein as novel biomarkers for sarcoidosis using proteomics of serum extracellular vesicles
por: Futami, Yu, et al.
Publicado: (2022)

Quantitative evaluation of emphysema for predicting immunotherapy response in patients with advanced non-small-cell lung cancer
por: Noda, Yoshimi, et al.
Publicado: (2022)

Monitoring antibody binding to T cells in a pembrolizumab‐treated patient with lung adenocarcinoma on hemodialysis
por: Osa, Akio, et al.
Publicado: (2019)

Pulmonary metastases of lung adenocarcinoma mimicking COVID-19 pneumonia
por: Shiroyama, Takayuki, et al.
Publicado: (2020)

Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports
por: Koba, Taro, et al.
Publicado: (2017)

Leucine-rich a-2 glycoprotein as a potential biomarker of idiopathic multicentric Castleman disease with pulmonary involvement: a single-center case-control study from Japan
por: Takata, So, et al.
Publicado: (2022)

Disseminated non-tuberculous mycobacterial infection caused by Mycobacterium obuense in an immunocompromised patient: a case report
por: Naito, Maiko, et al.
Publicado: (2023)

Proteomics of serum extracellular vesicles identifies a novel COPD biomarker, fibulin-3 from elastic fibres
por: Koba, Taro, et al.
Publicado: (2021)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Real-world impact of antifibrotics on prognosis in patients with progressive fibrosing interstitial lung disease
por: Niitsu, Takayuki, et al.
Publicado: (2023)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Fatal cytomegalovirus pneumonia in a critically ill patient with COVID‐19
por: Amiya, Saori, et al.
Publicado: (2021)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

The content of mutant EGFR DNA correlates with response to EGFR-TKIs in lung adenocarcinoma patients with common EGFR mutations
por: Hung, Ming-Szu, et al.
Publicado: (2016)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

Dynamics of EGFR mutations in plasma recapitulates the clinical response to EGFR-TKIs in NSCLC patients
por: Xiong, Liwen, et al.
Publicado: (2017)

Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way
por: Attili, Ilaria, et al.
Publicado: (2020)

Acquired resistance to third-generation EGFR-TKIs and emerging next-generation EGFR inhibitors
por: Du, Xiaojing, et al.
Publicado: (2021)

Treatment with immune checkpoint inhibitors after EGFR‐TKIs in EGFR ‐mutated lung cancer
por: Ito, Takashi, et al.
Publicado: (2021)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Novel agents and strategies for overcoming EGFR TKIs resistance
por: Niu, Fei-Yu, et al.
Publicado: (2014)

Adjuvant EGFR-TKIs-based therapy: are we ready?
por: Tam, Terence
Publicado: (2020)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

HSP90 inhibition overcomes EGFR amplification‐induced resistance to third‐generation EGFR‐TKIs
por: Watanabe, Sho, et al.
Publicado: (2021)

Outcomes of salvage lung resections in advanced EGFR ‐mutant lung adenocarcinomas under EGFR TKIs
por: Chen, Ying‐Yuan, et al.
Publicado: (2021)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
por: Zhou, Cefan, et al.
Publicado: (2022)

Efficacy of EGFR‐TKIs with or without upfront brain radiotherapy for EGFR‐mutant NSCLC patients with central nervous system metastases
por: Saida, Yu, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6qpruapu5h5s0nnpme4ar4qoe1